Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
– Study in HFpEF patients did not meet primary endpoint; company discontinuing development of praliciguat in HFpEF –– Conference call […]